Sugi Predict

Sugi Predict / Compounds / SCHEMBL852498

SCHEMBL852498

SCHEMBL852498

COC(=O)CC1CCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ GLS O94925 4/20 0.46
▸ EPHX1 P07099 1/20 0.46
▸ NR1H2 P55055 1/20 0.46
▸ HPGD P15428 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ IDO1 P14902 1/20 0.43
▸ TDO2 P48775 1/20 0.43
▸ USP30 Q70CQ3 1/20 0.43
▸ BRD4 O60885 1/20 0.43
▸ RECQL P46063 1/20 0.43
▸ PTPN2 P17706 1/20 0.42
▸ PTPN1 P18031 1/20 0.42
▸ PTPN6 P29350 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19511364 1.00 KDM4E (0.47) KDM4EPKMGLSEPHX1NR1H2
SCHEMBL20565243 1.00 KDM4E (0.47) KDM4EPKMGLSEPHX1NR1H2
SCHEMBL1048156 0.92 GLS (0.54) GLSEPHX1NR1H2HPGDALDH1A1
SCHEMBL1048155 0.92 GLS (0.54) GLSEPHX1NR1H2HPGDALDH1A1
SCHEMBL30922668 0.92 GLS (0.54) GLSEPHX1NR1H2HPGDALDH1A1
SCHEMBL106242 0.91 KDM4E (0.52) KDM4EPKMGLSEPHX1NR1H2
SCHEMBL31189316 0.91 NR1H2 (0.48) KDM4EPKMGLSEPHX1NR1H2
SCHEMBL31588543 0.91 NR1H2 (0.48) KDM4EPKMGLSEPHX1NR1H2
SCHEMBL25957458 0.91 NR1H2 (0.48) KDM4EPKMGLSEPHX1NR1H2
Hydrochloric Acid SCHEMBL4219415 0.90 KDM4E (0.51) KDM4EPKMGLSEPHX1NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4587014-A2 C5AR1 ANTAGONISTS AND USES THEREOF Vanqua Bio, Inc. (US) 2025-07-23 — — EP disclosed
WO-2025059577-A1 SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS ATAVISTIK BIO, INC. (US) 2025-03-20 — — WO disclosed
US-20250011338-A1 Kinase Inhibitors and Uses Thereof DENALI THERAPEUTICS INC. (US) 2025-01-09 — — US disclosed
EP-4472968-A1 INHIBITORS OF RAF KINASES PIERRE FABRE MEDICAMENT (FR) 2024-12-11 — — EP disclosed
US-12129263-B2 Kinase inhibitors and uses thereof DENALI THERAPEUTICS INC. (US) 2024-10-29 — — US disclosed
US-20240182467-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2024-06-06 — — US disclosed
CN-117980293-A Hydroxamic acid compound with ENPP1 inhibitory activity and application thereof 上海海和药物研究开发股份有限公司 2024-05-03 — — CN disclosed
WO-2024059096-A2 C5AR1 ANTAGONISTS AND USES THEREOF VANQUA BIO, INC. (US) 2024-03-21 — — WO disclosed
US-11814384-B2 Inhibtors of Raf kinases KINNATE BIOPHARMA INC. (US) 2023-11-14 — — US disclosed
US-20230303566-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2023-09-28 — — US disclosed
EP-2433937-A1 Substituted-quinoxaline-type-piperidine compounds and the uses thereof Purdue Pharma LP (US) 2012-03-28 — — EP disclosed
US-20100216726-A1 Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof PURDUE PHARMA L.P. (US) 2010-08-26 — — US disclosed
US-20100216726-A1 Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof PURDUE PHARMA L.P. (US) 2010-08-26 — — US disclosed
WO-2009027820-A2 SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF PURDUE PHARMA L.P. (DE) 2009-03-05 — — WO disclosed
EP-1385508-B1 DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO INC (US) 2008-05-21 — — EP disclosed
US-7026316-B2 Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes MERCK & CO., INC. (US) 2006-04-11 — — US disclosed
EP-1385508-A4 DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO INC (US) 2005-06-08 — — EP disclosed
US-20040106656-A1 Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes MERCK SHARP & DOHME CORP. 2004-06-03 — — US disclosed
EP-1385508-A1 DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES Merck & Co., Inc. (US) 2004-02-04 — — EP disclosed
WO-2002076450-A1 DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO., INC. (US) 2002-10-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106656-A1 Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes DPP4, DPP3, DPP7 KDM4E 1732/4885PKM 1624/4885GLS 206/4885
US-20100216726-A1 Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof P2RX4, P2RX5, P2RX3 KDM4E 965/4885PKM 537/4885GLS 87/4885
US-20250011338-A1 Kinase Inhibitors and Uses Thereof MAP3K20, MAP3K6, MAP3K19 KDM4E 1312/4885PKM 527/4885GLS 697/4885
US-20240182467-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF KDM4E 1831/4885PKM 1907/4885GLS 1016/4885
US-20230303566-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF KDM4E 1831/4885PKM 1907/4885GLS 1016/4885
US-11814384-B2 Inhibtors of Raf kinases RAF1, BRAF, ARAF KDM4E 3091/4885PKM 2028/4885GLS 862/4885
US-12129263-B2 Kinase inhibitors and uses thereof MAP3K20, MAP3K6, MAP3K19 KDM4E 1312/4885PKM 527/4885GLS 697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.